Clinical development of src family kinase inhibitors in malignant melanoma

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

Full text not currently available from Enlighten.

Abstract

Currently available systemic therapies for malignant melanoma are unsatisfactory and there is an urgent need for effective and well tolerated drugs for use in both early and advanced disease. The Src family of cytoplasmic tyrosine kinases (SFKs) have been implicated in the regulation of many of the hallmarks of malignancy making them attractive targets in solid tumours including melanoma. The first generation of selective SFK inhibitors to enter the clinic (AZD0530, dasatinib, bosutinib) have demonstrated safety, tolerability and target modulation in phase I trials. Phase II trials in patients with advanced melanoma are now planned in the USA and Europe. Here we discuss the rationale for, and challenges facing, the successful development of SFK inhibitors in melanoma. Furthermore, as dasatinib is also a potent inhibitor of the receptor tyrosine kinase (RTK), c-Kit, we reconsider the utility of targeting this kinase in the light of recent molecular epidemiological data.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert and MacPherson, Dr Iain and Evans, Professor Jeff
Authors: MacPherson, I., Jones, R., and Evans, T.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Open Cancer Journal
ISSN:1874-0790

University Staff: Request a correction | Enlighten Editors: Update this record